This post was originally published on this sitehttps://i-invdn-com.akamaized.net/news/LYNXMPEB2404R_M.jpg
Investing.com – AbbVie (NYSE:) reported on Friday fourth quarter that beat analysts’ forecasts and revenue that was inline with expectations.
AbbVie announced earnings per share of $2.21 on revenue of $8.70B. Analysts polled by Investing.com anticipated EPS of $2.19 on revenue of $8.7B. That with comparison to EPS of $1.9 on revenue of $8.31B in the same period a year before. AbbVie had reported EPS of $2.33 on revenue of $8.48B in the previous quarter. Analysts are expecting EPS of $2.11 and revenue of $8.02B in the upcoming quarter.
AbbVie shares are down 1% from the beginning of the year , still down 5.23% from its 52 week high of $91.99 set on December 20, 2019. They are under-performing the which is up 3.12% year to date.
AbbVie shares gained 1.86% in pre-market trade after the report.
AbbVie follows other major Healthcare sector earnings this month
AbbVie’s report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.